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Abstract
Objective. Electronic cigarettes (e-cigs) are an emerging
trend, yet little is known about their use in the cancer popu-
lation. The objectives of this study were (1) to describe
characteristics of e-cig use among cancer patients, (2) to
define e-cig advertising exposure, and (3) to characterize
perceptions of traditional cigarettes versus e-cigs.
Study Design. Cross-sectional study.
Setting. Comprehensive cancer center.
Subjects and Methods. Inpatient, current smokers with a
cancer diagnosis. E-cig exposure and use were defined using
descriptive statistics. Wilcoxon rank test was used to com-
pare perceptions between e-cigs and traditional cigarettes.
Results. A total of 979 patients were enrolled in the study; 39
cancer patients were identified. Most cancer patients were
women (59%), with an average age of 53.3 years. Of the
patients, 46.2% reported e-cig use, most of which (88.9%) was
‘‘experimental or occasional.’’ The primary reason for e-cig use
was to aid smoking cessation (66.7%), alternative use in non-
smoking areas (22.2%), and ‘‘less risky’’ cigarette replacement
(5.6%). The most common sources for e-cig information were
TV (76.9%), stores (48.7%), friends (35.9%), family (30.8%), and
newspapers or magazines (12.8%). Compared with cigarettes,
e-cigs were viewed as posing a reduced health risk (P\ .001)
and conferring a less negative social impression (P \ .001).
They were also viewed as less likely to satisfy nicotine cravings
(P = .002), to relieve boredom (P = .0005), to have a calming
effect (P\.001), and as tasting pleasant (P = .006)
Conclusions. E-cig use and advertising exposure are common
among cancer patients. E-cig use is perceived as healthier
and more socially acceptable but less likely to produce a
number of desired consequences of cigarette use.
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C
igarette smoking after a cancer diagnosis has been
shown to increase the risk of adverse outcomes,
including disease recurrence, poor quality of life,
wound-healing complications, and mortality.1,2 Conversely,
smoking cessation has been shown to be protective and to
lead to better treatment outcomes in cancer patients.3-5 For
this reason, tobacco cessation for cancer patients is strongly
advocated by oncology professionals, including the
American Society of Clinical Oncology.6 Traditional meth-
ods for smoking cessation include counseling and pharma-
cotherapy, such as nicotine replacement or other
medications designed to reduce withdrawal.7 Vaping
devices, often known as electronic cigarettes (e-cigs),
emerged on the market in the United States in 2007 and
have rapidly gained popularity.8 E-cigs are noncombustible
devices that vaporize a liquid that contains nicotine; the
liquid comes in a variety of flavors, and there is a wide var-
iation in delivery devices.9 In the past several years, the use
of e-cigs has increased. US general population surveys
showed that use of e-cigarette ever use in the population
increased from 3.3% in 2010 to 8.5% in 2013.10 Current use
was found to be highest in cigarette smokers and increased
from 4.9% in 2010 to 9.4% in 2012.10 In the current smoker
1Department of Otolaryngology, University of Alabama at Birmingham,
Birmingham, Alabama, USA
2Division of Pulmonary, Allergy & Critical Care Medicine, University of
Alabama at Birmingham, Birmingham, Alabama, USA
3Department of Health Behavior, School of Public Health, University of
Alabama at Birmingham, Birmingham, Alabama, USA
4Department of Otolaryngology, Indiana University School of Medicine,
Indianapolis, Indiana, USA
This article was presented at the 2015 Deep South Regional
Otolaryngology Annual Meeting; June 2015; Destin, Florida.
Corresponding Author:
Erin J. Buczek, MD, Department of Otolaryngology–Head and Neck
Surgery, University of Alabama at Birmingham, BDB 563, 1720 2nd Ave
South, Birmingham AL 35294, USA.
Email: epartington@uabmc.edu
Creative Commons CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution 4.0 License
(http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without
further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-
access-at-sage).
population, 32% had ever tried e-cigarettes.8 Unfortunately,
little is known about the safety, efficacy for smoking cessa-
tion, exposure, perceptions, and general use of e-cigs among
the vulnerable and high-risk cancer population. This study
aimed, therefore, to investigate e-cig exposure, use, and per-
ceptions among individuals with cancer.
Methods
Study Design
This cross-sectional study was performed at a National
Cancer Institute–designated Comprehensive Cancer
Center–associated hospital between December 2012 and
September 2013. The University of Alabama at Birmingham
Institutional Review Board approved the study protocol. All
inpatients older than 18 years of age and identified as a cur-
rent smoker on hospital admission were approached for
enrollment in the observational study. Patients met inclusion
criteria if they verified current smoking within the past 30
days and had a documented cancer diagnosis based on ICD-
9 codes. This included all cancer diagnoses and was not
specific to head and neck cancer. Further data regarding
specific cancer type, stage, or outcomes were not available.
Exclusion criteria included any patient not physically or
cognitively able to participate in the study and non-English
speakers. All participants signed informed consent forms
prior to participation.
Survey Components
Data were collected regarding demographics, e-cig use,
and e-cig information or advertising exposure sources.
Desire to quit smoking and confidence in quitting were
assessed using a 0 (not at all) to 10 (very high) response
scale. The Brief Smoking Consequences Questionnaire–Adult
(BSCQ-A) assessed cigarette-specific expectancy domains
on 10 scales: Negative Affect Reduction, Stimulation/
State Enhancement, Health Risks, Taste/Sensorimotor
Manipulation, Social Facilitation, Weight Control, Craving/
Addiction, Negative Physical Feelings, Boredom Reduction,
and Negative Social Impression.11 Patients rated items on
each scale using a Likert-type scale ranging from 0 (com-
pletely unlikely) to 9 (completely likely). An analogous set of
BSCQ-A items was administered to assess expectancies spe-
cific to e-cig use, using the same response scale as above.12
All patients were assessed on cigarette and e-cig–specific
expectancy domains.
Statistics
Descriptive statistics were used to report patient demo-
graphics, e-cig use, and e-cig advertising exposure. Mean
values of the cigarette-specific BSCQ-A were compared
with those of the e-cig–specific BSCQ-A using the
Wilcoxon ranked sign test (IBM SPSS Statistics 21.0, New
York, New York). A Wilcoxon ranked sign test was used
due to nonnormal data. A critical absolute Z value of 1.96
was used to reject the null hypothesis with a 95% confi-
dence interval.
Results
Of 979 current smokers enrolled in the observational study, 39
carried a current cancer diagnosis at the time of hospital admis-
sion. Demographic details are listed in Table 1. Most partici-
pants were women, with an average age of just less than 50
years. Approximately three-fifths of the cohort were white, and
approximately half reported at least some college education.
All cancer patients had heard of e-cigs and reported ini-
tial exposure from a variety of sources (Figure 1). The
most common general sources of e-cig information were
television (76.9%), followed by stores (48.7%), friends
(35.9%), family (30.8%), Internet advertisements (10.3%),
magazines (5.1%), radio (5.1%), newspaper (5.1%), and
health care providers (5.1%). Only 9 patients (23%) actively
sought out e-cig information on their own; the remaining
77% encountered the information passively. Patients report
viewing a median of 10 e-cig advertisements in the past 6
months (range = 3-840). The most common sources of spe-
cifically e-cig media advertising exposure were radio or TV
(79.5%), stores (38.5%), newspapers or magazines (12.8%),
and the internet (7.7%).
Of the 18 cancer patients (46.2%) reporting previous
e-cig use, 38.9% (n = 7) had used them in the past 30 days.
Among users, reasons for e-cig use included to help quit
smoking cigarettes (66.7%), to have something to smoke in
nonsmoking areas (22.2%), and to use as a less risky prod-
uct compared with traditional cigarettes (5.6%). One patient
did not know why he or she used e-cigs. With respect to fre-
quency of e-cig use, 50% reported ‘‘experimental’’ use,
38.9% ‘‘occasional’’ use, and 11.1% ‘‘regular’’ use. Most
Table 1. Demographic Information.
Frequency %
Average age, y 49.33 (range, 21-69)
Gender
Men 16 41.0
Women 23 59.0
Race
White 22 56.4
Black 15 38.5
American Indian 1 2.6
Native Indian 1 2.6
Education
Some high school or less 8 20.5
High school graduate 7 17.9
GED 4 10.3
Some college 16 41.0
4-y degree or higher 4 10.3
Marital status
Married or domestic partner 15 38.5
Separated 4 10.3
Divorced 7 17.9
Widowed 3 7.7
Never married 10 25.6
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patients reported a significant desire to quit smoking, with
89.7% scoring a 6 or greater on the 10-point scale. Most
patients reported high confidence that they would be suc-
cessful in quitting, with 79.5% scoring 6 or greater. The
remaining 21 cancer patients (53.8%) enrolled in the study
had never used e-cigs. On a scale of 1 (not at all likely) to
10 (very likely), 59.0% of nonusers reported they would be
likely to use e-cigs in the future (score of 6 or greater).
Patients who had tried e-cigs had seen a mean of 85 (SD =
202) ads in the past 6 months compared with 24 (SD = 49)
for those who had not tried e-cigs (P = .27).
All cancer patients were surveyed regarding expectancies
toward cigarettes and e-cigs. Six of the 10 BSCQ-A expec-
tancy scales were significantly different between cigarettes
and e-cigs: Negative Affect Reduction, Health Risks, Taste/
Sensorimotor Manipulation, Craving/Addiction, Boredom
Reduction, and Negative Social Impression (Table 2).
Compared with cigarettes, e-cigs were viewed as less likely
to relieve negative affect. They were also viewed as less of a
health risk compared with cigarettes. Participants also thought
they would be less likely to enjoy the taste of e-cigs and that
e-cigs would be less likely to satisfy their craving for nico-
tine. E-cigs were also perceived as less likely to reduce bore-
dom than cigarettes and as conferring a less negative social
impression (ie, less social stigma). The remaining 4 expec-
tancy constructs did not differ between cigarettes and e-cigs.
Discussion
E-cigarette Use
Electronic cigarettes have gained tremendous popularity
since emerging onto the American market in 2007.
However, many questions remain regarding exposure, per-
ceptions, safety, and efficacy for smoking cessation. In addi-
tion, a paucity of data exists regarding e-cig use among
hospitalized smokers,13 particularly cancer patients.
In our small study, we report a 46.6% rate of e-cig use
among current smokers with cancer. This rate exceeds pre-
viously published reports of 38.5% in 2013.14 In addition, it
exceeds the rate in the general population, in which e-cig
use falls between 7.9% to 32%,9,15 and it is similar to the
rate reported for the general population of smokers in the
same hospital.16 One possible explanation for increase in
e-cig use is aggressive advertising. E-cig advertising expen-
ditures have increased from $6.4 million in 2011 to $18.3
million in 2012.17,18 Our study identified a variety of
sources exposing cancer patients to e-cig information and
advertising. Advertisements specifically portray e-cigs as
healthier nicotine alternatives, less expensive, and more
effective in smoking cessation.17 This study did confirm
several of these advertising messages. Specifically, e-cigs
were perceived as less of a health risk and more socially
acceptable compared with cigarettes. However, in this
cohort of cancer patients, there was no perceived difference
between e-cigs and cigarettes when it came to appetite sup-
pression, physical side effects (ie, throat irritation), social
facilitation, and stimulating effects. In addition, some nega-
tive perceptions toward e-cigs were elucidated, such as e-
cigs were perceived as less likely to satisfy nicotine crav-
ings, not taste as good as traditional cigarettes, less likely to
reduce negative affect, and less likely to reduce boredom.
With the vast majority of patients exposed to advertising
for e-cigs, it is imperative to understand how this marketing
is influencing both smokers and nonsmokers alike.
Figure 1. Sources of initial e-cigarette exposure.
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Understanding perceptions of e-cigs is particularly impor-
tant given the uncertainty regarding the safety and efficacy
of e-cigs for smoking cessation.15,19,20 It is also salient for
cancer patients who are strongly encouraged by health care
providers to quit smoking and, therefore, are more likely to
seek products they perceive as helpful in smoking cessation.
While cigarette advertising has been regulated since the
1970s, e-cig advertising is unhindered, and advertisements
are pervasive on television, social media, and magazines.21
Youth and adolescents are particularly susceptible to these
outlets and are frequently exposed to e-cig advertisements.
Previous research has shown that most smokers try their
first cigarette as young adults. As more tobacco products
enter the market, those who otherwise may not have tried
cigarettes could be more inclined to use novel tobacco prod-
ucts.22 Youth are particularly susceptible to influences by
media and advertising.23 Recent research has shown that
youth who have tried e-cigs are more open to trying cigar-
ettes.18 This increase in advertising coupled with susceptible
youth could lead to e-cigs becoming a potential ‘‘gateway’’
into using traditional cigarettes.
E-cigarette Safety
This study documents a perception that e-cigs are less
unhealthy than cigarettes. Preliminary studies do indicate
that there is less health risk than with cigarettes. In one
recent study, cellular carcinogenic effects on oral cavity
mucosa were studied in 3 groups: cigarette smokers, e-cig
users, and nonsmokers.24 There were significantly fewer
cytologic changes in the e-cig group compared with the
cigarette group, implying improved cancer risk.24 While
there are data to support that e-cigs are less toxic than cigar-
ettes, the safety and potential harm of e-cigs have not been
definitively established.9
In counseling patients, it is important to note that e-cigs
are currently unregulated and sold by a variety of manufac-
turers; thus, the specific liquid contents (and nicotine con-
centration) vary and are often unknown.9,25 While reports
indicate that e-cigs contain lower levels of harmful chemi-
cals than cigarettes do,26 e-cigs do contain carcinogens
such as formaldehyde.27 Thus, while cancer patients view
e-cigarettes as less unhealthy, long-term data are unavail-
able about the potential health risks of e-cigs relative to
cigarettes. There are also no data with respect to how e-cigs
might affect cancer therapy and outcomes.
Counseling Patients on E-cigarettes as a Smoking
Cessation Aid
Understanding patient rationale for e-cig use is imperative
for health care providers to successfully counsel cancer
patients in smoking cessation. In this study, 46.2% of
patients cited using e-cigs as an aid to smoking cessation;
however, their efficacy for smoking cessation remains to be
determined. This important point must be disclosed to
patients trying to quit smoking. This responsibility will fall
on the health care industry as opposed to the advertising
and e-cig industry.
While patients often use e-cigs as an aid to quit cigarette
use, the evidence on their efficacy is conflicting. A recent
Cochrane Review of 2 small prospective randomized trials
concluded that e-cigs help long-term smoking cessation
when compared with placebo e-cigs.28 One of the studies
compared nicotine-containing e-cigs to both nicotine-free
e-cigs and the transdermal nicotine patch; the authors found
that whereas rates of abstinence were not statistically differ-
ent between the 3 groups, nicotine-containing e-cigs had the
highest quit rate.29 A small prospective trial identified 23%
of e-cigarette users achieving 30-day cigarette abstinence,
and one-third reduced cigarette consumption by at least
50%.30 However, other studies indicate that e-cigs may be
less effective for smoking cessation. A 2011 survey revealed
that e-cigs were associated with an unsuccessful quit
attempt.31 E-cigs have also been found to be associated with
a reduction in smoking, but actual cessation rates did not
differ between e-cig users and nonusers.32 In another large
cross-sectional survey in the United Kingdom, those
Table 2. Perceptions of E-cigarettes versus Traditional Cigarettes.a
Mean for E-cigarettes Mean for Traditional Cigarettes Z Valueb P Value
Negative Affect Reduction 4.61 6.62 3.560 \.001
Stimulation/State Enhancement 3.23 2.85 0.061 .951
Health Risks 5.12 8.20 4.289 \.001
Taste/Sensorimotor Manipulation 4.29 6.10 2.768 .006
Social Facilitation 2.72 3.22 0.996 .319
Weight Control 2.64 3.71 1.690 .091
Craving/Addiction 4.70 6.66 3.127 .002
Negative Physical Feelings 2.61 2.99 0.725 .468
Boredom Reduction 3.89 5.40 2.811 .005
Negative Social Impression 3.39 5.20 3.485 \.001
aGroup means are based on the average from several questions related to the topics as scored from 0 = completely unlikely to 9 = completely likely.
bAbsolute Z values greater than 1.96 are sufficient to reject the null hypothesis using 95% confidence intervals for each comparison.
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attempting to quit with e-cigs smoked more cigarettes and
were more dependent as measured by strength of urges as
opposed to those who quit ‘‘cold turkey’’ (ie, without any
pharmacotherapy or without e-cigs).15
Limited information is available about e-cig use among
cancer patients. One survey found that e-cig users were just
as likely to smoke at follow-up as compared with nonusers
and that a higher average number of cigarettes were smoked
per day among e-cig users.14 The preliminary data, there-
fore, do not support the efficacy of e-cigs for smoking ces-
sation among individuals with cancer. Practitioners should
take care to recommend empirically supported interventions,
including behavioral counseling and approved pharma-
cotherapies (ie, nicotine replacement therapies, bupropion,
and varenicline) and exercise caution and encourage skepti-
cism with regard to e-cigs.
Conclusion
Cancer patients are a high-risk population portending worse
health outcomes with continued cigarette use. E-cig adver-
tising is pervasive. With the increasing popularity of e-cigs,
a high proportion of cancer patients who smoke have used
e-cigs because they are perceived as a less unhealthy alter-
native and more socially acceptable as compared with cigar-
ettes. Additional research and cancer patient education are
required because the short- and long-term health risks and
benefits of e-cigarettes remain unknown.
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